Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials

BACKGROUND: Patients with severe hypertriglyceridaemia (sHTG) are often refractory to lipid‐lowering therapy. Apolipoprotein (Apo) CIII inhibition could be promising to treat subjects with sHTG. The antisense oligonucleotide against APOC3 mRNA volanesorsen was recently introduced to treat sHTG. We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Calcaterra, Ilenia, Lupoli, Roberta, Di Minno, Alessandro, Di Minno, Matteo Nicola Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Systematic Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788245/
https://www.ncbi.nlm.nih.gov/pubmed/35851450
http://dx.doi.org/10.1111/eci.13841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788245/
https://www.ncbi.nlm.nih.gov/pubmed/35851450
http://dx.doi.org/10.1111/eci.13841

Ejemplares similares